p53

Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

FDA Approves Phase I Study Design for Cellceutix's Anti-Cancer Drug Kevetrin

An expanded license with Dana-Farber Cancer Institute for an offshoot of its Cold-PCR technology allows Transgenomic to develop kits that can detect mutations in common cancer-related genes such as KRAS and P53 directly from blood samples and then analyze the variants using multiple sequencing approaches.

The data, while preliminary, suggests that the drug might require a companion diagnostic to establish p53 status prior to treatment, company officials said.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.